ImClone Receives Payment From Merck KGaA For Changes To Erbitux Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone consented to Merck’s sublicense of certain IP rights relating to anti-EGFR antibody technology to Takeda.
You may also be interested in...
Erbitux Patent Winner Opens Door To Deal With ImClone
ImClone seeks declaratory judgment invalidating disputed patent.
Erbitux Patent Winner Opens Door To Deal With ImClone
ImClone seeks declaratory judgment invalidating disputed patent.
ImClone Will Remain Independent, But Seeks To Partner Oncology Candidates
Erbitux developer is recruiting a permanent CEO after the board of directors completes a review of strategic alternatives.